| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Per Hove Thomsen, Merete Juul Sørense. [Evidence for psychopharmacological treatment of depression in children and adolescents?]. Ugeskrift for laeger. vol 169. issue 14. 2007-05-10. PMID:17437688. |
emphasis is put on treatment with selective serotonin reuptake inhibitors as these are the best-documented agents in the treatment of depression in children and adolescents. |
2007-05-10 |
2023-08-12 |
Not clear |
| Mark Hyman Rapaport, Michael E Thas. Translating the evidence on atypical depression into clinical practice. The Journal of clinical psychiatry. vol 68. issue 4. 2007-05-10. PMID:17474801. |
selective serotonin reuptake inhibitors (ssris), selective norepinephrine reuptake inhibitors (snris), tricyclic antidepressants (tcas), and monoamine oxidase inhibitors (maois) have been studied for the treatment of atypical depression. |
2007-05-10 |
2023-08-12 |
Not clear |
| Charles B Nemerof. Recent advances in the neurobiology of depression. Psychopharmacology bulletin. vol 36 Suppl 2. 2007-05-03. PMID:12490820. |
considerable experimental and clinical evidence supports the fundamental roles of serotonin and norepinephrine, as well as the interactions between these systems in the etiology of depression. |
2007-05-03 |
2023-08-12 |
Not clear |
| Martin B Kelle. Long-term treatment strategies in affective disorders. Psychopharmacology bulletin. vol 36 Suppl 2. 2007-05-03. PMID:12490822. |
the data reviewed in this article indicate that both selective serotonin reuptake inhibitors (ssris) and the serotonin and norepinephrine reuptake inhibitor (snri) venlafaxine are effective in reducing the incidence of relapse during 6 months of continuation therapy for major depression. |
2007-05-03 |
2023-08-12 |
Not clear |
| Jack M Gorman, Robert M A Hirschfeld, Philip T Nina. New developments in the neurobiological basis of anxiety disorders. Psychopharmacology bulletin. vol 36 Suppl 2. 2007-05-03. PMID:12490823. |
hence, there may be a neurobiological link between gad and depression through the activity of the serotonin and norepinephrine systems. |
2007-05-03 |
2023-08-12 |
Not clear |
| Johan A den Boer, Dwight L Evans, Sing Lee, Rafael Salin-Pascua. Unraveling the diagnostic clues of depression and GAD: the primary care challenge. Psychopharmacology bulletin. vol 36 Suppl 2. 2007-05-03. PMID:12490831. |
antidepressants are effective as monotherapy in comorbid patients, and newer agents such as selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors have been shown to be effective in the treatment of anxiety and depression. |
2007-05-03 |
2023-08-12 |
Not clear |
| Mary-Anne Enoc. Genetic and environmental influences on the development of alcoholism: resilience vs. risk. Annals of the New York Academy of Sciences. vol 1094. 2007-05-02. PMID:17347351. |
for example, it has been shown that childhood maltreatment interacts with a monoamine oxidase a (maoa) gene variant to predict antisocial behavior that is often associated with alcoholism, and an interaction between early life stress and a serotonin transporter promoter variant predicts alcohol abuse in nonhuman primates and depression in humans. |
2007-05-02 |
2023-08-12 |
Not clear |
| J Seiderer, C Rust, M Menth, T Pusl, M Jun. [A 67-year-old patient with somnolence and severe hyponatraemia]. Der Internist. vol 47. issue 6. 2007-05-01. PMID:16767477. |
a 67-year-old female patient with known depression was admitted to the intensive care unit with severe hyponatraemia (105 mmol/l) and somnolence caused by inadequate antidiuretic hormone secretion (siadh) syndrome after starting therapy with the selective serotonin reuptake inhibitor (ssri) citalopram. |
2007-05-01 |
2023-08-12 |
Not clear |
| Emilio Varea, José Miguel Blasco-Ibáñez, María Angeles Gómez-Climent, Esther Castillo-Gómez, Carlos Crespo, Francisco José Martínez-Guijarro, Juan Náche. Chronic fluoxetine treatment increases the expression of PSA-NCAM in the medial prefrontal cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 4. 2007-05-01. PMID:16900104. |
as the expression of psa-ncam is increased by serotonin in other cerebral regions, antidepressants acting on serotonin reuptake may influence psa-ncam expression and thus counteract the effects of depression by modulating neuronal structural plasticity. |
2007-05-01 |
2023-08-12 |
rat |
| F López-Muñoz, C Alamo, G Rubio, P García-García, A Pard. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry. vol 40. issue 1. 2007-04-25. PMID:17327955. |
reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. |
2007-04-25 |
2023-08-12 |
Not clear |
| F López-Muñoz, C Alamo, G Rubio, P García-García, A Pard. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry. vol 40. issue 1. 2007-04-25. PMID:17327955. |
treatment-resistant depression is a relatively common clinical occurrence: between 60-70% of depressive patients fail to achieve total remission to the initial treatment with selective serotonin reuptake inhibitors (ssri). |
2007-04-25 |
2023-08-12 |
Not clear |
| Tatsui Otsuka, Takashi Togo, Naoya Sugiyama, Kumi Uehara, Asuka Yoshimi, Aya Karashima, Hiromi Shioya, Yoshio Hirayas. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17166643. |
future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory ocd with depression. |
2007-04-24 |
2023-08-12 |
Not clear |
| Danielle M Dick, Jevon Plunkett, Damara Hamlin, John Nurnberger, Sam Kuperman, Marc Schuckit, Victor Hesselbrock, Howard Edenberg, Laura Bieru. Association analyses of the serotonin transporter gene with lifetime depression and alcohol dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample. Psychiatric genetics. vol 17. issue 1. 2007-04-17. PMID:17167343. |
association analyses of the serotonin transporter gene with lifetime depression and alcohol dependence in the collaborative study on the genetics of alcoholism (coga) sample. |
2007-04-17 |
2023-08-12 |
Not clear |
| Danielle M Dick, Jevon Plunkett, Damara Hamlin, John Nurnberger, Sam Kuperman, Marc Schuckit, Victor Hesselbrock, Howard Edenberg, Laura Bieru. Association analyses of the serotonin transporter gene with lifetime depression and alcohol dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample. Psychiatric genetics. vol 17. issue 1. 2007-04-17. PMID:17167343. |
the objective of this study was to analyze association of the serotonin transporter gene 5-httlpr polymorphism on lifetime depression and alcohol dependence in the collaborative study on the genetics of alcoholism sample. |
2007-04-17 |
2023-08-12 |
Not clear |
| Maria A Oquendo, Ramin S Hastings, Yung-Yu Huang, Norman Simpson, R Todd Ogden, Xian-Zhang Hu, David Goldman, Victoria Arango, Ronald L Van Heertum, J John Mann, Ramin V Parse. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Archives of general psychiatry. vol 64. issue 2. 2007-04-16. PMID:17283287. |
as in major depression, selective serotonin reuptake inhibitors targeting brain serotonin transporters are first-line treatments for bipolar depression. |
2007-04-16 |
2023-08-12 |
Not clear |
| Maria A Oquendo, Ramin S Hastings, Yung-Yu Huang, Norman Simpson, R Todd Ogden, Xian-Zhang Hu, David Goldman, Victoria Arango, Ronald L Van Heertum, J John Mann, Ramin V Parse. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Archives of general psychiatry. vol 64. issue 2. 2007-04-16. PMID:17283287. |
associations of serotonin transporter promoter polymorphisms and bipolarity have been reported; however, research on alterations in serotonergic neurotransmission in bipolar depression remains scant. |
2007-04-16 |
2023-08-12 |
Not clear |
| Junko Ishikawa, Akinori Ishikawa, Shoji Nakamur. Interferon-alpha reduces the density of monoaminergic axons in the rat brain. Neuroreport. vol 18. issue 2. 2007-04-10. PMID:17301678. |
recent studies suggest that the degeneration of axons containing serotonin and noradrenaline is involved in the pathophysiology of depression. |
2007-04-10 |
2023-08-12 |
rat |
| Rainald Mössner, Peter Riedere. Allelic variation of a functional promoter polymorphism of the serotonin transporter and depression in Parkinson's disease. Parkinsonism & related disorders. vol 13. issue 1. 2007-04-05. PMID:16935546. |
allelic variation of a functional promoter polymorphism of the serotonin transporter and depression in parkinson's disease. |
2007-04-05 |
2023-08-12 |
Not clear |
| O A Levada, N V Cherednichenko, I R Ryba. [Serum serotonin level in patients with depression and panic attacks]. Likars'ka sprava. issue 5-6. 2007-04-05. PMID:17380868. |
[serum serotonin level in patients with depression and panic attacks]. |
2007-04-05 |
2023-08-12 |
Not clear |
| O A Levada, N V Cherednichenko, I R Ryba. [Serum serotonin level in patients with depression and panic attacks]. Likars'ka sprava. issue 5-6. 2007-04-05. PMID:17380868. |
serum serotonin level (ssl) was studied using elisa method in 21 patients with depression associated with panic attacks (pa) and 15 non-depressed patients (8--with pa, 7--with the autonomous nervous system dysfunction). |
2007-04-05 |
2023-08-12 |
Not clear |